Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2005

View Archived Issues

Phase III Targretin studies in front-line NSCLC fail to meet endpoints

Antiinflammatory and antiapoptotic properties of MX-1153

Novel dihydroquinolines with broad-spectrum activity against multiple herpesviruses

Telavancin receives fast track designations

Novel human glucagon receptor antagonist discovered

FDA approval for Xibrom

iNOS inhibitor with prominent antiinflammatory effects

Full approval for Velcade in second-line multiple myeloma

Immunosuppressant agents reported by Poseidon Pharmaceuticals

Anti-IGF-1R antibody in clinical phase I trials

ACHP inhibits myeloma cell growth and sensitizes myeloma cells to chemotherapeutic agents

Enrollment suspended in Clevelox phase III safety trials

Highlights of the 15th Annual Meeting of the American Glaucoma Society

Tacrolimus 0.03% cream reported safe and effective in atopic dermatitis

Anticonvulsants show promise in the management of impulsive aggression

New atiprimod trial in advanced cancers

Phase II study of IC-485 in COPD fails to meet primary endpoint

Protein Design Labs plots Nuvion development pathway

Good safety results for Theratechnologies' GLP-1 analogue

Zilver PTX stent studied for peripheral arterial disease

New title added to Drug R&D Backgrounders series: Nicotine Addiction

Rasagiline improves fluctuations in levodopa-treated Parkinson's disease patients

New treatments for respiratory disorders described in patent literature

Chemokine CXCR3 receptor inhibitors emerge from Celltech R&D

Complement inhibitors for neurodegenerative, autoimmune disorders disclosed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...